BioPharmSignal logoBioPharmSignal

Biotech News

Artivion Reports Second Quarter 2026 Financial Results

Artivion (AORT)ArtivionEarnings

Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the second quarter of 2026 was $(13.5)

Related news

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

TMCITreace Medical Concepts2026-08-07 11:05 EST

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

APYXApyx Medical2026-08-06 20:05 EST

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

PLSEPulse Biosciences2026-08-06 20:05 EST

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

SENSSenseonics2026-08-06 20:01 EST

Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results

XTNTXtant Medical2026-08-06 12:00 EST

Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026

SGHTSight Sciences2026-08-05 20:05 EST

Sight Sciences Reports Second Quarter 2026 Financial Results

NEPHNephros2026-08-05 20:00 EST

Nephros Schedules Second Quarter 2026 Financial Results Conference Call

View all latest news

Artivion

Aortic-Disease Technologies Artivion develops medical devices and implantable tissues for complex aortic and cardiac surgery. Its portfolio is designed around the needs of cardiac and vascular surgeons treating life-threatening aortic disease. Surgical Products The company supplies aortic stent grafts, surgical adhesives, mechanical...

Recent company news

AORTArtivion2026-08-06 20:05 EST

Artivion Reports Second Quarter 2026 Financial Results

AORTArtivion2026-07-28 20:10 EST

Artivion to Participate in Upcoming Investor Conferences

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

AORTArtivion2026-06-29 11:00 EST

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

AORTArtivion2026-06-10 20:10 EST

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Stock data

Close
26.57 USD
Market cap
991.26M USD
Exchange
NYSE
Sector
MedTech
Location
United States